| Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial P Novak, R Schmidt, E Kontsekova, N Zilka, B Kovacech, R Skrabana, ... The Lancet Neurology 16 (2), 123-134, 2017 | 299 | 2017 |
| Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo N Zilka, P Filipcik, P Koson, L Fialova, R Skrabana, M Zilkova, G Rolkova, ... FEBS letters 580 (15), 3582-3588, 2006 | 293 | 2006 |
| First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an … E Kontsekova, N Zilka, B Kovacech, P Novak, M Novak Alzheimer's research & therapy 6, 1-12, 2014 | 277 | 2014 |
| A walk through tau therapeutic strategies S Jadhav, J Avila, M Schöll, GG Kovacs, E Kövari, R Skrabana, LD Evans, ... Acta neuropathologica communications 7, 1-31, 2019 | 254 | 2019 |
| Who fans the flames of Alzheimer's disease brains? Misfolded tau on the crossroad of neurodegenerative and inflammatory pathways N Zilka, Z Kazmerova, S Jadhav, P Neradil, A Madari, D Obetkova, ... Journal of neuroinflammation 9, 1-9, 2012 | 159 | 2012 |
| Assessment of severity and progression of canine cognitive dysfunction syndrome using the CAnine DEmentia Scale (CADES) A Madari, J Farbakova, S Katina, T Smolek, P Novak, T Weissova, ... Applied Animal Behaviour Science 171, 138-145, 2015 | 128 | 2015 |
| Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies J Hanes, N Zilka, M Bartkova, M Caletkova, D Dobrota, M Novak Journal of neurochemistry 108 (5), 1167-1176, 2009 | 124 | 2009 |
| FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer’s disease P Novak, R Schmidt, E Kontsekova, B Kovacech, T Smolek, S Katina, ... Alzheimer's research & therapy 10, 1-16, 2018 | 117 | 2018 |
| Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease E Kontsekova, N Zilka, B Kovacech, R Skrabana, M Novak Alzheimer's research & therapy 6, 1-16, 2014 | 116 | 2014 |
| Human misfolded truncated tau protein promotes activation of microglia and leukocyte infiltration in the transgenic rat model of tauopathy N Zilka, Z Stozicka, A Kovac, E Pilipcinec, O Bugos, M Novak Journal of neuroimmunology 209 (1-2), 16-25, 2009 | 110 | 2009 |
| Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats M Hrnkova, N Zilka, Z Minichova, P Koson, M Novak Brain research 1130, 206-213, 2007 | 99 | 2007 |
| AADvac1, an active immunotherapy for Alzheimer’s disease and non Alzheimer tauopathies: an overview of preclinical and clinical development P Novak, N Zilka, M Zilkova, B Kovacech, R Skrabana, M Ondrus, ... The journal of prevention of Alzheimer's disease 6, 63-69, 2019 | 95 | 2019 |
| First transgenic rat model developing progressive cortical neurofibrillary tangles P Filipcik, N Zilka, O Bugos, J Kucerak, P Koson, P Novak, M Novak Neurobiology of aging 33 (7), 1448-1456, 2012 | 95 | 2012 |
| The tangled story of Alois Alzheimer N Zilka, M Novak Bratislavske lekarske listy 107 (9/10), 343, 2006 | 95 | 2006 |
| Mesenchymal stem cells rescue the Alzheimer's disease cell model from cell death induced by misfolded truncated tau N Zilka, M Zilkova, Z Kazmerova, M Sarissky, V Cigankova, M Novak Neuroscience 193, 330-337, 2011 | 93 | 2011 |
| Microglia display modest phagocytic capacity for extracellular tau oligomers P Majerova, M Zilkova, Z Kazmerova, A Kovac, K Paholikova, B Kovacech, ... Journal of Neuroinflammation 11, 1-12, 2014 | 90 | 2014 |
| Neuroinflammation in Alzheimer's disease: protector or promoter? N Zilka, M Ferencik, I Hulin Bratislavske lekarske listy 107 (9-10), 374-383, 2006 | 89 | 2006 |
| Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load P Koson, N Zilka, A Kovac, B Kovacech, M Korenova, P Filipcik, M Novak European Journal of Neuroscience 28 (2), 239-246, 2008 | 88 | 2008 |
| ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease P Novak, B Kovacech, S Katina, R Schmidt, P Scheltens, E Kontsekova, ... Nature aging 1 (6), 521-534, 2021 | 86 | 2021 |
| Ten years of tau-targeted immunotherapy: the path walked and the roads ahead P Novak, E Kontsekova, N Zilka, M Novak Frontiers in neuroscience 12, 798, 2018 | 86 | 2018 |
